Information:
Error:
ID
41219
Description
A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.; ODM derived from: https://clinicaltrials.gov/show/NCT01144403
Link
https://clinicaltrials.gov/show/NCT01144403
Keywords
Versions (1)
- 7/18/20 7/18/20 -
Copyright Holder
See clinicaltrials.gov
Uploaded on
July 18, 2020
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Lymphoma, B-Cell NCT01144403
Eligibility Lymphoma, B-Cell NCT01144403
- StudyEvent: Eligibility
Similar models
Eligibility Lymphoma, B-Cell NCT01144403
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Adult | Age
Item
adult patients, >/=18 years of age
boolean
C0001675 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0001779 (UMLS CUI [2])
Mantle cell lymphoma Untreated | Ineligibility Autologous hematopoietic stem cell transplant
Item
untreated mantle cell lymphoma, not eligible for autologous stem cell transplantation
boolean
C0334634 (UMLS CUI [1,1])
C0332155 (UMLS CUI [1,2])
C1512714 (UMLS CUI [2,1])
C2193200 (UMLS CUI [2,2])
C0332155 (UMLS CUI [1,2])
C1512714 (UMLS CUI [2,1])
C2193200 (UMLS CUI [2,2])
MIPI - Mantle Cell Lymphoma International Prognostic Index
Item
known mantle cell lymphoma international prognostic index (mipi) at diagnosis
boolean
C4706335 (UMLS CUI [1])
ECOG performance status
Item
ecog performance status 0-2
boolean
C1520224 (UMLS CUI [1])
Hematologic function | Renal function | Liver function
Item
adequate hematological, renal and hepatic function
boolean
C0221130 (UMLS CUI [1])
C0232804 (UMLS CUI [2])
C0232741 (UMLS CUI [3])
C0232804 (UMLS CUI [2])
C0232741 (UMLS CUI [3])
Hypersensitivity Murine protein | Hypersensitivity Chemotherapy
Item
known hypersensitivity to murine proteins or chemotherapy regimen
boolean
C0020517 (UMLS CUI [1,1])
C1699668 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0392920 (UMLS CUI [2,2])
C1699668 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0392920 (UMLS CUI [2,2])
First line treatment Previous
Item
previous first-line therapy
boolean
C1708063 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0205156 (UMLS CUI [1,2])
Cancer Other | Exception Squamous cell carcinoma | Exception Basal cell carcinoma | Exception Carcinoma in situ of uterine cervix
Item
history of other malignancy within the last 5 years, except for squamous cell carcinoma, basal cell carcinoma of the skin or in situ cervical carcinoma
boolean
C1707251 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0007137 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0007117 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0851140 (UMLS CUI [4,2])
C1705847 (UMLS CUI [2,1])
C0007137 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0007117 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0851140 (UMLS CUI [4,2])
Communicable Disease
Item
active infection
boolean
C0009450 (UMLS CUI [1])
Heart Disease
Item
clinically significant cardiac disease
boolean
C0018799 (UMLS CUI [1])
Steroid therapy Regular
Item
regular corticosteroid treatment in the 4 weeks prior to first dose of study drug
boolean
C0149783 (UMLS CUI [1,1])
C0205272 (UMLS CUI [1,2])
C0205272 (UMLS CUI [1,2])